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Diamond-Blackfan anemia (DBA) is a rare congenital red-cell aplasia characterized by anemia, bone-marrow erythro-
blastopenia, and congenital anomalies and is associated with heterozygous mutations in the ribosomal protein (RP) S19
gene (RPS19) in ∼25% of probands. We report identiﬁcation of de novo nonsense and splice-site mutations in another
RP, RPS24 (encoded by RPS24 [10q22-q23]) in ∼2% of RPS19 mutation–negative probands. This ﬁnding strongly suggests
that DBA is a disorder of ribosome synthesis and that mutations in other RP or associated genes that lead to disrupted
ribosomal biogenesis and/or function may also cause DBA.
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Diamond-Blackfan anemia (DBA [MIM 105650]) is a con-
genital form of red-cell aplasia with marked clinical het-
erogeneity and an increased risk ofmalignancy.1–3 Affected
individuals usually present in infancy or in early child-
hood with pallor due to severe macrocytic anemia. Al-
though anemia is a prominent feature of DBA, the disease
is also characterized by growth retardation and congenital
anomalies, in particular of the head, neck, upper limbs,
and urinary system, which are present in∼40%of patients,
reﬂecting the fact that DBA is a broad disorder of devel-
opment.1,4–6 Laboratory ﬁndings such as increased mean
corpuscular volume (MCV), elevated erythrocyte adeno-
sine deaminase activity (eADA), and elevated hemoglobin
F (HbF) are observed in a majority of but not all patients
with DBA.7 In addition, the anemia may be mild or absent
in some individuals within affected families, with only
subtle indications of the erythroid abnormality, such as
increased MCV and/or eADA. The ﬁrst DBA gene, RPS19,
was identiﬁed on chromosome 19q13.28 and was found
to be mutated in ∼25% of probands with both sporadic
and familial DBA.8–11 This highly conserved ribosomalpro-
tein (RP) gene encodes a 16-kDa protein, RPS19, that binds
to the 40S ribosomal subunit as 1 of 33 associatedproteins.
Recently, the RPS19 protein was shown to play an im-
portant role in 18S rRNA ribosomal biogenesis,12 but its
exact function(s) in translation and role(s) in erythropoi-
esis are unknown.
To identify other gene(s) involved inDBA,we performed
a genomewide linkage screen and subsequently sequenced
candidate genes. Here, we report that another RP gene,
RPS24, is mutated in ∼2% of probands with DBA.
A total of 215 families participated in the study; 47 fam-
ilies were multiplex and 168 families comprised only one
affected individual. Informed consent for genetic analyses
was obtained from all subjects in the study. The diagnosis
of DBA was based on the ﬁndings of normochromic ane-
mia, increased eADA, reticulocytopenia, and a low num-
ber or lack of erythroid precursors in the bone marrow,
often associated with congenital malformations. In a few
individuals, the DBA diagnosis was made on the basis of
a family history of the disease and elevated eADA and/or
MCV. Blood samples were obtained from affected individ-
uals and their family members, and genomic DNA (gDNA)
was isolated according to standard procedures.
We performed a genomewide linkage screen, using
GeneChip Human Mapping 10K Array Xba (Affymetrix)
on an extensive family comprising 10 informative meio-
ses (ﬁg. 1a). The SNP mapping data were analyzed using
a multipoint parametric model and the MERLIN pedi-
gree-analysis package.13 The analysis was run assuming
autosomal dominant inheritance, a gene frequency of
0.000001, and a penetrance of 1.0. We found evidence
favoring linkage of the DBA phenotype to a 17.5-Mb re-
gion on chromosome 8q and to regions on chromosomes
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Figure 1. Phenotype and genotype cosegregation in family MA-
1. Squares represent males, circles represent females, blackened
symbols represent clinically affected individuals who presented
with severe anemia (I-1 and II-7 depend on small steroid doses,
and II-2 has been in steroid-induced remission since childhood
and presented with webbed neck), open symbols represent unaf-
fected individuals, and line-shaded symbols represent clinically
unaffected individuals with abnormal laboratory tests, such as
elevated eADA and HbF. a, Phenotype of family MA-1. np Normal
range. b, Genotype of family MA-1. Nonsense mutation c.316CrT
(Gln106STOP) was found in clinically affected individuals I-1, II-
2, and II-7 and in two apparently healthy individuals, III-2 and
III-3, with elevated eADA and HbF. wt p Wild type.






Mutation DNA Mutation Exon or Intron RNA Change
Predicted Protein
Change
D1 Familial 5 c.316CrT Exon 4 r.316cru Gln106STOP
D2 Sporadic 1 c.46CrT Exon 2 r.46cru Arg16STOP
D3 Familial 2 c.4–14delGTTTATGTTTTCAG;
c.4_6delACC/insTACGGATAG
Intron 1/Exon 2 r.4_69del (skipped exon 2) Del 22 aa (N1_M2del)
NOTE.—Primer sequences and ampliﬁcation conditions are available on request. Del p deletion.
10 and 6 (5.8 Mb and 3.8 Mb, respectively). We focused
our attention on RP genes RPS20 and RPL7, present in the
critical region on chromosome 8q, and on RPS24, located
in the linked region on chromosome 10. We sequenced
exons, intron-exon boundaries, and the promoter regions
of these genes in the proband from this family. Sequence
results for RPS20 and RPL7 were normal; in contrast, we
found a heterozygous nonsense mutation (316CrT) in
exon 4 of RPS24 (in sample D1) (table 1). As predicted by
the linkage data, further sequencing of RPS24 in all family
members revealed complete cosegregation of the 316CrT
mutation with the DBA phenotype. Four other affected
family members carry the same mutation, whereas ﬁve
unaffected individuals are homozygous for the wild-type
sequence (ﬁg. 1b). There is no phenotype-genotype cor-
relation among the affected family members, as shown in
ﬁgure 1. The 316CrT mutation causes the change of glu-
tamine to a stop codon and is predicted to result in for-
mation of a truncated RPS24 protein.
Subsequently, we sequenced RPS24 (NCBI accession
number NC_000010.9) in 215 unrelated probands with
DBA, representing both familial and sporadic cases. Thirty
had documented RPS19 mutations, whereas 185 had no
known mutations. Among patients with no RPS19 mu-
tations, we found another nonsense mutation in exon 2
in transfusion-dependent patient D2 and a combined de-
letion/insertion of the intron 1–exon 2 boundary resulting
in skipped exon 2 in steroid-dependent patient D3 and in
his father (table 1). The father does not currently have any
sign of anemia; however, during childhood, he presented
with multiple congenital heart anomalies, elevated eADA,
and moderate anemia, which was resistant to iron treat-
ment and, at the time, was attributed to his cardiac ab-
normalities. To control for sequence variation, we se-
quenced RPS24 in 210 control individuals from an
ethnically matched population and did not ﬁnd any of
the above-mentioned sequence changes, consistent with
our belief that these sequence variations are pathogenic
mutations.
The human RPS24 gene includes six exons that encode
an RP that is a component of the 40S ribosomal subunit.14
Xu and colleagues14 found that human RPS24 encodes
RPS24 protein isoforms a and c, of length 130 and 133 aa,
respectively, as a result of alternative 3′-end splicing into
mRNA variants 1 and 2 (ﬁg. 2a). These variants show tis-
sue-speciﬁc differences in expression pattern.14 The mu-
rine Rps24 gene comprises seven exons with three alter-
natively spliced transcript variants 1, 2, and 3.14,15 To
explore the normal role of RPS24 and to consider how its
dysfunction might result in DBA, we performed RT-PCR
on mRNA from 20 normal human tissues (Clontech), in-
cluding whole bone marrow. Reverse transcription and
PCR ampliﬁcation were accomplished using One-step RT-
PCR kit (Qiagen) with primers that span 240 bp at the 3′
end of the coding region (forward primer: gtggtggcaagaca-
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Figure 2. Structure of human RPS24 gene. a, Schema of the two variants of human RPS24, NCBI accession numbers NM_033022
(variant 1) and NM_001026 (variant 2), as a result of alternative 3′-end mRNA splicing.14 Variant 1 contains exons I–V and encodes
RPS24 isoform a (130 aa) (NP_148982). Exon V encodes the stop codon (tga). Variant 2 contains exons I–IV and VI and encodes RPS24
isoform c (133 aa) (NP_001017). Exon VI encodes 3 aa, PKE. b, Schema of the novel human RPS24 variant 3, which contains exons
I–IV and VII and encodes the 131-aa RPS24 isoform (isoform b). Below it is the sequence of the novel human RPS24 transcript variant
3. The ATG in bold uppercase letters represents the start codon. Alternatively spliced 3′ end of transcript variant 3 encodes Lys (AAA
[red uppercase letters]) followed by stop codon tga. Red lowercase letters represent the untranslated region of exon VII, green letters
represent untranslated exon V, and blue letters represent untranslated exon VI of the novel RPS24 transcript variant 3.






DCT RPS24 Variant 2 
GAPDH
RPS24 (Variant 2)
Normalized to GAPDH ( )DCT2
Fetal liver 28.32  .23 20.65  .09 7.67  .24 .004927 (.004163–.005832)
Fetal brain 40.00  .00 20.01  .11 19.99  .11 .000001 (.000001–.000001)
Brain (cerebellum) 22.30  .13 18.51  .32 3.79  .34 .072293 (.056937–.091790)
Brain (whole) 40.00  .00 19.29  .12 20.71  .12 .000001 (.000001–.000001)
Thymus 24.75  .27 20.16  .21 4.59  .34 .041666 (.032954–.052680)
Salivary gland 30.83  .51 20.49  .24 10.34  .57 .000770 (.000520–.001142)
Adrenal gland 34.68  1.21 20.40  .21 14.28  1.23 .000050 (.000021–.000118)
Thyroid 31.59  .97 20.81  .09 10.78  .98 .000569 (.000289–.001120)
Skeletal muscles 40.00  .00 17.31  .20 22.69  .20 .000000 (.000000–.000000)
Lung 27.07  .18 21.37  .14 5.70  .23 .019303 (.016445–.022658)
Bone marrow 24.17  .18 20.81  .14 3.36  .23 .097396 (.083041–.114232)
Trachea 32.33  .85 21.16  .17 11.17  .87 .000434 (.000238–.000793)
Spinal cord 32.95  1.57 19.53  .38 13.41  1.62 .000092 (.000030–.000281)
Placenta 28.27  .16 20.99  .27 7.28  .31 .006434 (.005183–.007987)
Heart 40.00  .00 18.30  .19 21.70  .19 .000000 (.000000–.000000)
Uterus 40.00  .00 20.98  .20 19.03  .20 .000002 (.000002–.000002)
Testis 24.03  .10 20.44  .42 3.59  .43 .083043 (.061694–.111779)
Prostate 37.84  1.92 21.36  .42 16.48  1.96 .000011 (.000003–.000043)
Kidney 32.81  .68 19.14  .17 13.67  .70 .000077 (.000047–.000124)
NOTE.—CT p number of quantitative PCR cycles.
actgg; reverse primer: agtggccacagctaacatca). Control re-
actions without reverse transcriptase were used to exclude
contamination of the cDNA by gDNA. The size of the RT-
PCR products was detected on 1.3% agarose gels, and RT-
PCR products were puriﬁed and sequenced to determine
exact splice junctions. The results revealed a third novel
mRNA variant (variant 3) present in several human tis-
sues—fetal and adult brain, skeletal muscle, and heart—
and a lack of variant 2 in these tissues (ﬁg. 3a). The mRNA
variant 3 encodes a 131-aa isoform (ﬁg. 2b) identical to
Figure 3. Expression of RPS24 mRNA in normal human tissues. a, RPS24 RT-PCR products from 20 human tissues visualized on a 1.3%
agarose gel. Novel variant 3 is present in fetal brain, adult brain, heart, and skeletal muscle. glp Gland. b, Tissue-speciﬁc expression
of variant 2 and total RPS24 mRNA in human tissues, measured by qrt-PCR. Four arrows indicate four tissues where no variant 2 mRNA
was detected. c, Tissue-speciﬁc expression of total RPS24 and RPS19 mRNA. (All results of qrt-PCR are normalized to reference gene
GAPDH.)
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to GAPDH ( )DCT2
Fetal liver 24.64  .40 20.57  .39 4.07  .56 .06 (.04–.09)
Fetal brain 20.98  .15 20.01  .22 .97  .26 .51 (.42–.61)
Brain (cerebellum) 21.16  .21 18.31  .23 2.86  .31 .14 (.11–.17)
Brain (whole) 25.22  .16 19.19  .20 6.02  .25 .02 (.01–.02)
Thymus 22.37  .17 20.05  .29 2.33  .34 .20 (.16–.25)
Salivary gland 23.42  .27 20.57  .30 2.86  .41 .14 (.10–.18)
Adrenal gland 22.12  .24 20.30  .15 1.82  .28 .28 (.23–.34)
Thyroid 21.39  .25 20.57  .32 .82  .40 .57 (.43–.75)
Skeletal muscles 23.52  .11 17.13  .11 6.38  .16 .01 (.01–.01)
Lung 22.28  .26 21.29  .23 .99  .35 .50 (.39–.64)
Bone marrow 22.27  .35 20.46  .38 1.82  .52 .28 (.20–.41)
Trachea 23.37  .20 20.98  .25 2.39  .32 .19 (.15–.24)
Spinal cord 23.12  .40 19.08  .46 4.04  .61 .06 (.04–.09)
Placenta 23.32  .26 21.01  .33 2.32  .42 .20 (.15–.27)
Heart 22.24  .07 18.51  .05 3.73  .09 .08 (.07–.08)
Uterus 23.34  .24 20.90  .21 2.44  .32 .18 (.15–.23)
Testis 21.62  .31 20.11  .16 1.51  .35 .35 (.27–.45)
Prostate 21.86  .28 20.99  .36 .87  .46 .55 (.40–.75)
Kidney 24.57  .23 18.99  .36 5.59  .42 .02 (.02–.03)
NOTE.—CT p number of quantitative PCR cycles.









to GAPDH ( )DCT2
Fetal liver 22.42  .17 20.30  .10 2.13  .20 .23 (.20–.26)
Fetal brain 19.41  .10 19.96  .04 .55  .10 1.46 (1.36–1.57)
Brain (cerebellum) 20.80  .25 18.36  .26 2.44  .36 .18 (.14–.24)
Brain (whole) 23.99  .20 18.94  .26 5.05  .33 .03 (.02–.04)
Thymus 20.10  .19 19.97  .16 .13  .24 .91 (.77–1.08)
Salivary gland 21.06  .14 20.42  .09 .64  .17 .64 (.57–.72)
Adrenal gland 20.69  .28 20.33  .08 .37  .29 .78 (.63–.95)
Thyroid 20.24  .13 20.64  .23 .40  .26 1.32 (1.10–1.58)
Skeletal muscles 22.66  .48 17.42  .39 5.23  .62 .03 (.02–.04)
Lung 20.96  .10 21.28  .04 .31  .11 1.24 (1.15–1.34)
Bone marrow 20.73  .22 20.34  .06 .38  .23 .77 (.65–.90)
Trachea 21.60  .29 20.81  .27 .79  .39 .58 (.44–.76)
Spinal cord 20.95  .31 19.22  .08 1.73  .32 .30 (.24–.38)
Placenta 20.51  .18 20.71  .22 .20  .28 1.15 (.94–1.40)
Heart 23.39  .33 18.50  .17 4.89  .37 .03 (.03–.04)
Uterus 21.36  .22 20.93  .07 .43  .23 .74 (.63–.87)
Testis 20.81  .19 19.96  .15 .85  .24 .56 (.47–.66)
Prostate 20.72  .14 20.77  .07 .05  .16 1.04 (.93–1.15)
Kidney 22.78  .16 19.00  .19 3.78  .24 .07 (.06–.09)
NOTE.—CT p number of quantitative PCR cycles.
murine Rps24 protein isoform 3 (NCBI accession number
NP_207635).14 Quantitative real-time PCR (qrt-PCR), with
primers and probes designed to exclusively amplify hu-
man variant 2 mRNA, conﬁrmed lack of that mRNA in
the four above-mentioned tissues (table 2 and ﬁg. 3b).
Interestingly, qrt-PCRs amplifying total human RPS24 and
RPS19 mRNAs revealed a tissue-speciﬁc variation in ex-
pression level. Mature tissues, such as adult brain, skeletal
muscle, heart, and kidney, expressed low levels of both
transcripts, whereas tissues and organs with signiﬁcant
populations of proliferating cells, such as fetal brain, pla-
centa, bone marrow, and various glandular organs, con-
tained signiﬁcantly higher levels, supporting the notion
that absolute levels of RP synthesis correlate with cell pro-
liferation.16 We found coordinate expression of both genes
in the majority of tissues studied (ﬁg. 3c and tables 3 and
4) as was previously found in yeast.17 RPS24 and RPS19
transcripts were quantiﬁed using Assays-by-Design or
Assays-on-Demand gene-expression kits (Applied Biosys-
tems) as described elsewhere.18
To determine splice-site pattern in speciﬁc subsets of
bone marrow from three populations, the primitive
(CD34CD71CD45RA), erythroid (CD34CD71
CD45RA), and myeloid (CD34CD71CD45RA) progen-
itors were separated as described elsewhere,18 and mRNA
from these as well as peripheral blood and lymphoblastoid
cell lines were tested by RT-PCR. We found that all tested
hematopoietic cells express transcript variants 1 and 2,
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Figure 4. Differently spliced mRNA variants of RPS24 in human hematological tissues. The three bone-marrow cell populations, primitive
(CD34CD71CD45RA), erythroid (CD34CD71CD45RA), and myeloid (CD34CD71CD45RA) progenitors, and peripheral blood and
lymphoblastoid cell lines express variants 1 and 2, which encode isoforms a and c, in different proportions. There is increasing expression
of variant 2 with maturation of hematological cells. RNA samples were obtained from three unrelated controls.
Figure 5. Expression of RPS24 mRNA and RPS24 protein in control and diseased lymphoblastoid cell lines. (All results of qrt-PCR are
normalized to reference gene GAPDH.) a, RPS24 and RPS19 mRNA expression in control and diseased lymphoblastoid cell lines. b, RPS24
and RPS19 protein expression in control and diseased lymphoblastoid cell lines. Quantiﬁcation of the RPS24 and RPS19 protein levels
normalized to GAPDH was performed with the Quantity One version 4.2.1 software (Bio-Rad Laboratories) on Image Station 440 (Kodak
DS). C1–C4 are control samples; D1–D9 are diseased samples. MW p molecular weight.
which encode isofoms a and c, in different proportions.
There is an increasing expression of variant 2 with the
maturation of the hematological cells (ﬁg. 4).
qrt-PCR showed a reduced level of total RPS24 mRNA
from lymphoblastoid cell lines in both probands (D1 and
D3) with nonsense mutations (ﬁg. 5a and table 5) and
premature stop codons, suggesting degradation of mutated
transcript due to nonsense-mediated decay,19 whereas the
RPS19 mRNA level in these patients was normal or ele-
vated (ﬁg. 5a and table 6). To correlate these ﬁndings with
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to GAPDH ( )DDCT2
Controls:
C1–C4 20.13  .66 16.38  .36 3.94  .76 .00  1.07 1.0 (.48–2.10)
RPS24-mutated samples:
D1 22.39  .28 17.56  .22 4.84  .36 .90  .84 .54 (.30–.96)
D2 20.83  .31 17.44  .17 3.39  .35 .55  .83 1.47 (.82–2.61)
D3 20.82  .33 16.25  .31 4.67  .45 .73  .88 .60 (.33–1.11)
RPS19-mutated samples:
D4 19.68  .35 16.38  .24 3.30  .42 .64  .87 1.56 (.86–2.84)
D5 20.54  .38 18.21  .14 2.34  .41 1.60  .86 3.04 (1.67–5.51)
D6 20.50  .69 16.35  .27 4.14  .74 .20  1.06 .87 (.42–1.81)
Non–RPS19/RPS24-mutated samples:
D7 20.80  .82 17.20  .40 3.60  .91 .34  1.18 1.27 (.56–2.87)
D8 20.80  .71 18.69  .36 2.11  .80 1.83  1.10 3.56 (1.66–7.61)
D9 19.86  .33 16.49  .23 3.37  .40 .57  .85 1.49 (.82–2.69)
D10 19.45  .46 17.16  .35 2.29  .57 1.65  .95 3.15 (1.63–6.08)
NOTE.—C1–C4 are control samples, and D1–D10 are diseased samples. CT p number of cycles; CT,C p number of control cycles.










to GAPDH ( )DDCT2
Controls:
C1–C4 18.00  .56 16.46  .48 1.78  .74 .00  1.04 1.0 (.49–2.06)
RPS24-mutated samples:
D1 18.30  .10 17.82  .13 .48  .17 1.30  .76 2.46 (1.46–4.15)
D2 17.79  .16 17.49  .23 .30  .28 1.48  .79 2.78 (1.61–4.81)
D3 17.81  .32 16.49  .30 1.47  .44 .31  .86 1.24 (.68–2.24)
RPS19-mutated samples:
D4 17.60  .14 16.70  .05 .90  .14 .87  .75 1.83 (1.09–3.09)
D5 19.25  .05 18.20  .05 1.06  .07 .72  .74 1.65 (.99–2.76)
D6 19.43  .21 16.64  .21 2.78  .30 1.01  .80 .50 (.29–.87)
Non–RPS19/RPS24-mutated samples:
D7 19.04  .31 17.33  .08 1.71  .32 .07  .80 1.05 (.60–1.83)
D8 19.15  .28 19.11  .11 .04  .30 1.74  .80 3.33 (1.92–5.78)
D9 17.68  .47 16.61  .18 1.07  .51 .71  .89 1.63 (.88–3.04)
D10 17.46  .20 17.28  .24 .18  .31 1.60  .80 3.03 (1.74–5.28)
NOTE.—C1–C4 are control samples, and D1–D10 are diseased samples. CT p number of cycles; CT,C p number of control cycles.
protein levels, western-blot experiments were performed
as described elsewhere9; the RPS24 protein was detected
with rabbit polyclonal antibodies raised to puriﬁed rat
liver Rps24/2320 and with anti-rabbit IgG horseradish per-
oxidase-conjugated antibodies (Upstate Biotechnology).
Subsequently, the membrane was stripped and was repro-
bed with the rabbit polyclonal RPS19 antibody9 and anti-
rabbit IgG horseradish peroxidase-conjugated antibodies
(Upstate Biotechnology) to detect the RPS19 protein.
Compared with control samples, the results revealed a
reduction of RPS24 protein in lymphoblastoid cell lines
from all three mutated probands with nonsense and
splice-site mutations (D1–D3), as well as in D5 with a
splice-site mutation in RPS19 and a premature termina-
tion codon, which may result from nonsense-mediated
decay. We found a similar pattern of RPS24 and RPS19
protein levels in these patients, indicating coordinate
control of RP levels, as described elsewhere for several
other species21,22 (ﬁg. 5b). These data show that the steady-
state levels of both proteins are decreased in RPS24-
mutated samples, which may suggest that RPS24 is re-
quired for the assembly of RPS19 into ribosomal subunits.
If not assembled properly, free RPS19 is most likely un-
stable. In contrast, in RPS19-mutated samples, RPS19 pro-
tein levels in some samples decrease while RPS24 levels
remain high, suggesting that RPS24 may assemble into
ribosomal subunits in the absence of RPS19, thereby
achieving some level of stability.
To determine whether recruitment of mRNA to poly-
somes was impaired in patients with DBA, we separated
lymphoblast cell-line lysates from nine diseased (D1–D9)
and four control (C1–C4) individuals on sucrose gradients
as described elsewhere.23 Polysome:free ribosome ratios
were calculated using IgorPro software. We did not detect
any signiﬁcant difference in the RNA ratio of polysome-
bound:free ribosomal subunits between diseased and con-
trol samples ( ; data not shown). It is likely that lym-P ! .3
phoblasts, which are not defective in DBA, have a level
of RPS24 or RPS19 encoded by one allele sufﬁcient to form
ribosomes and mask an abnormality in translation, even
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though the mRNA and protein levels are decreased in
some patients.
In summary, our results indicate that the RPS24 gene is
a second gene for DBA,mutated in ∼2% of probands. Since
both RPS24 and RPS19 encode RPs, we consider other RP
genes to be excellent candidate genes for DBA, despite the
fact that a previous study found no mutations in three
other RP genes, RPS3a, RPS13, and RPS16, in several DBA
samples tested.24 It is likely that RP gene mutations are
quite infrequent in patients with DBA, making it impor-
tant to screen a large cohort of patients before concluding
that any particular gene is not involved.
Our data reinforce the notion that DBA is a ribosomal
disease with abnormal ribosomal biogenesis and, possibly,
function. Considering the broad range of functions in
which ribosomes are involved, our data support the no-
tion that a better understanding of ribosomal biogenesis
and function in DBA should lead to new insights into the
pathogenesis and treatment of this disease.
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